Insight

Nov 4, 2024, 12:24

Julian Downward: Mechanisms limiting responses of KRAS mutant lung cancer to KRAS inhibitors and immunotherapy

Julian Downward, Cancer biologist at the Francis Crick Institute, shared on X:

“In our new paper just out in Science Advances we investigate mechanisms that may be limiting responses of KRAS mutant lung cancer to KRAS inhibitors and immunotherapy.”

Spatial multiplex analysis of lung cancer reveals that regulatory T cells attenuate KRAS-G12C inhibitor–induced immune responses.

Authors: Megan Cole, Panayiotis Anastasiou, Claudia Lee, Xiaofei Yu, Andrea De Castro, Jannes Roelink, Chris Moore, Edurne Mugarza, Martin Jones, Karishma Valand, Sareena Rana, Emma Colliver, Mihaela Angelova, Katey S. S. Enfield, Alastair Magness, Asher Mullokandov, Gavin Kelly, Tanja D. De Gruijl, Miriam Molina-Arcas, Charles Swanton, Julian Downward, Febe Van Maldeghem.

Julian Downward

Alastair Magness Andrea De Castro Asher Mullokandov cancer Charles Swanton Chris Moore Claudia Lee Edurne Mugarza Emma Colliver Febe Van Maldeghem Gavin Kelly Jannes Roelink Julian Downward Karishma Valand Katey S. S. Enfield Martin Jones Megan Cole Mihaela Angelova Miriam Molina-Arcas OncoDaily Oncology Panayiotis Anastasiou Sareena Rana Tanja D. De Gruijl Xiaofei Yu

Neil Ranasinghe: What’s the Difference Between a Clinician and a Technical Author?

LOCKTAC Molecular Glues Are Changing the Rules of Drug Discovery - Amgen

Top 10 Immunotherapy Trials in Lung Cancer to Watch at ESMO 2025

FDA has Granted Full Market Approval for Papzimeos - NIH

Kirsty Duncan։ Thirty-two Months Into Fighting Cancer...